Anti-CD20 treatment prolongs syngeneic Islet graft survival and delays the onset of recurrent autoimmune diabetes

Hu, Changyun, Deng, Songyan, Wong, F. Susan ORCID: https://orcid.org/0000-0002-2812-8845 and Wen, Li 2008. Anti-CD20 treatment prolongs syngeneic Islet graft survival and delays the onset of recurrent autoimmune diabetes. Annals of the New York Academy of Sciences 1150 (1) , pp. 217-219. 10.1196/annals.1447.032

Full text not available from this repository.

Abstract

Type 1 diabetes is an autoimmune disease characterized by T cell–mediated destruction of pancreatic islet beta cells. Pancreatic islet transplantation with long-term immunosuppressive drug treatment is an accepted therapeutic option for patients with type 1 diabetes suffering from disabling hypoglycemia on insulin treatment. Here we investigated the replacement of immunosuppressive drug treatment with immune tolerance establishment induced by temporary B cell–depletion therapy for islet transplantation. The result suggested that the combined therapy of B cell depletion and syngeneic islet transplantation may reverse the disease in hCD20/NOD mice.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	Wiley-Blackwell
ISSN:	0077-8923
Last Modified:	03 Nov 2022 09:33
URI:	https://orca.cardiff.ac.uk/id/eprint/105282

Citation Data

Cited 7 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item